Journal of International Psychiatry

[Abstract] Objective To explore the clinical efficacy of low-dose olanzapine combined with paroxetine in the treatment of severe depression in the acute phase. Methods 77 patients with severe depression in the acute phase from January 2022 to October 2023 were randomly grouped according to the numerical table. Among them, 38 cases in the control group were treated with paroxetine, while 39 cases in the observation group were treated with low-dose olanzapine in combination. The anxiety, depression, emotions, and serum markers before and after treatment were compared. The adverse reactions during treatment were compared. Results After treatment, the Hamilton Anxiety/Depression Scale (HAMA/HAMD) decreased in both groups compared to before treatment, but the observation group had lower scores in both items after treatment (P<0.05). After treatment, the serum levels of 5-hydroxytryptamine (5-HT) and dopamine (DA) increased in both groups compared to before treatment. However, the average water levels of the two biomarkers in the observation group were higher after treatment (P<0.05). At 2, 4, and 8 weeks of treatment, there was no significant difference in the scores of the side reaction scales between the two groups (P>0.05). Conclusion The combination of low-dose olanzapine and paroxetine has a better therapeutic effect in the acute phase of severe depression, and does not significantly increase drug adverse reactions. The medication is safe and effective.

Key words Low Dose Olanzapine; Paroxetine; Severe Depression; Acute stage